Oral Ebola Drug Enters Phase 2 Trial in DRC Amid Largest-Ever Outbreak

For infectious disease specialists managing the Democratic Republic of Congo's escalating Ebola crisis, the standard of care presents an agonizing logistical divide. One camp of medical responders argues that intravenous antiviral infusions and antibody cocktails remain the only proven pharmacological tools to reduce mortality, insisting that field hospitals must be equipped to deliver them despite the immense strain. Conversely, public health logisticians and frontline coordinators contend that relying on IV drips in resource-poor, high-transmission zones is fundamentally unscalable, exposing healthcare workers to needle-stick injuries and severely capping the number of patients who can receive care. That tension over how to deliver therapeutics in a crisis zone forms the backdrop for a new clinical milestone: an oral antiviral gummy, NV-387, which began dosing patients in a Phase II clinical trial in the DRC's Ituri province last week.[1][5]

Developed by clinical-stage pharmaceutical company NanoViricides, NV-387 is currently the only orally administered drug in active human trials for Ebola virus disease. The Phase IIA/IIB trial, registered under the Pan African Clinical Trials Registry, commenced patient enrollment and dosing around September 23, 2026. The study is being conducted at an Ebola Treatment Center in Ituri province, the epicenter of the current outbreak, under the leadership of principal investigator Professor Patrick de Marie Chimusa Katoto, drawing on support from the University of Bukavu and regional health authorities.[1][4]

The trial arrives as the DRC battles the largest Ebola outbreak in its history, and the second-largest globally after the 2014–2016 West Africa epidemic. According to the latest data from the DRC health ministry and the Center for Infectious Disease Research and Policy, the outbreak has recorded 8,067 confirmed cases and 3,901 deaths since it was declared on May 15, 2026. That translates to a staggering case-fatality rate of 48.4 percent across 63 health zones in seven provinces, overwhelming local medical infrastructure.[2][3]

Unlike recent outbreaks driven by the Zaire ebolavirus, the current crisis is caused by the Bundibugyo ebolavirus. This virological distinction is critical: while the Zaire strain has approved vaccines and monoclonal antibody treatments deployed in previous years, the Bundibugyo virus currently has no approved vaccine or specific therapeutic protection. Medical teams on the ground have been forced to rely entirely on optimized supportive care and the off-label use of broad-spectrum antivirals, leaving a massive gap in the pharmacological arsenal available to frontline workers.[1][5]

NV-387 is designed as a broad-spectrum antiviral that mimics heparan sulfate proteoglycan, a host-cell surface molecule. Because a large proportion of viruses—including all known orthoebolaviruses—use this specific molecule as an attachment receptor before entering cells via endosomes, the drug aims to intercept and neutralize the virus before it can replicate. The chewable gummy formulation is specifically intended to bypass the need for cold-chain storage and intravenous administration, removing two of the most significant logistical barriers to treating hemorrhagic fevers in remote areas.[1][4]

The clinical program is structured in two distinct stages to ensure patient safety while moving rapidly toward efficacy data. The Phase IIA portion is a single-arm safety and dose run-in designed to establish a dosing protocol that is both safe and well-tolerated by patients experiencing severe disease symptoms. Researchers are aiming to identify the maximum feasible dose that avoids non-tolerable adverse events, maximizing the antiviral impact on the highly lethal Bundibugyo strain before locking in the protocol for the wider cohort.[1]

Once the optimal dosage is established and stratified by disease severity, the trial will transition directly into its Phase IIB stage. This phase will serve as a randomized, controlled, open-label efficacy evaluation with independent blinded-endpoint adjudication. It will directly measure whether the oral gummies, administered alongside optimized supportive care, can significantly improve survival rates compared to supportive care alone, providing the first rigorous clinical data on oral antiviral efficacy against an active Ebola outbreak in a real-world crisis setting.[1]

The implications of a successful oral therapeutic extend far beyond the current outbreak in the DRC. 'Our DRC Team and the CRO are committed to contribute to produce the best results for the patients, hoping to maximize survival,' said Anil R. Diwan, President of NanoViricides, in a statement announcing the trial's initiation. If NV-387 proves effective, it would radically shift the paradigm of viral hemorrhagic fever response, allowing health workers to distribute treatments rapidly in remote communities without the bottleneck of infusion infrastructure.[1][3]

Despite the promise of new therapeutics, the broader humanitarian response remains under severe pressure as the virus continues to spread. The International Organization for Migration has called for urgent international support, noting that insecurity, population displacement, and limited access to basic services in eastern DRC are severely hampering surveillance and contact tracing efforts. As the virus expands into new geographic areas, the race to validate and deploy scalable countermeasures like NV-387 has never been more critical to preventing further regional destabilization.[2][3]